Mobile

Phase I/II study to investigate the safety, tolerability, efficacy and pharmacokinetics of ZK 219477 in combination with cisplatin as first-line therapy in chemotherapy-naive patients with extensive-d...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-000067-29

Phase I/II study to investigate the safety, tolerability, efficacy and pharmacokinetics of ZK 219477 in combination with cisplatin as first-line therapy in chemotherapy-naive patients with extensive-disease (ED) stage small-cell lung cancer (SCLC)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Phase I-part: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of ZK 219477 in combination with cisplatin To investigate the safety and tolerability of ZK 219477 in combination with cisplatin Phase II-part: To evaluate the anti-tumor activity of ZK 219477 in combination with cisplatin in patients with chemotherapy-naive, extensive-disease stage small cell lung cancer

Critère d'inclusion

  • Extensive disease (ED) stage small-cell lung cancer (SCLC)

Liens